SCHEMBL9894823

SCHEMBL9894823

CC=C(C(=O)OC)c1ccccc1COc1ccc(/C(C)=N\O)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.46
HDAC8 Q9BY41 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
HPGD P15428 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
ALDH1A1 P00352 5/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 2/20 0.41
HTT P42858 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
CHEK1 O14757 1/20 0.39
PIM1 P11309 1/20 0.39
MAPK8 P45983 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9894754 0.96 HIF1A (0.50) HIF1AHDAC8SMN1; SMN2MEN1KMT2A
SCHEMBL9894824 0.92 HIF1A (0.44) HIF1AHDAC8SMN1; SMN2RAB9ANPC1
SCHEMBL9894822 0.92 HIF1A (0.44) HIF1AHDAC8SMN1; SMN2RAB9ANPC1
SCHEMBL9894821 0.92 HIF1A (0.44) HIF1AHDAC8SMN1; SMN2RAB9ANPC1
SCHEMBL9894752 0.88 HIF1A (0.48) HIF1AHDAC8SMN1; SMN2MEN1KMT2A
SCHEMBL9894750 0.88 HIF1A (0.48) HIF1AHDAC8SMN1; SMN2MEN1KMT2A
SCHEMBL9894755 0.88 HIF1A (0.48) HIF1AHDAC8SMN1; SMN2MEN1KMT2A
SCHEMBL9894838 0.87 PPARG (0.44) HIF1AHDAC8SMN1; SMN2RAB9ANPC1
SCHEMBL9894599 0.87 NPC1 (0.47) HIF1AHDAC8SMN1; SMN2RAB9ANPC1
SCHEMBL9895556 0.84 MAPT (0.52) HIF1AHDAC8SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US claimed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP claimed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US claimed
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US disclosed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP disclosed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME HIF1A, HIF1AN, EGLN3 HIF1A 1/4885HDAC8 3396/4885SMN1; SMN2 3764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.